Investing.com - Halozyme (NASDAQ: HALO) reported third quarter EPS of $0.75, $0.05 better than the analyst estimate of $0.70. Revenue for the quarter came in at $216M versus the consensus estimate of $218.7M.
Guidance
Halozyme sees FY 2023 EPS of $2.70-$2.80 versus the analyst consensus of $2.65.
Halozyme sees FY 2023 revenue of $825.00M-$845.00M versus the analyst consensus of $836.00M.
Halozyme's stock price closed at $35.26. It is down -19.92% in the last 3 months and down -23.81% in the last 12 months.
Halozyme saw 3 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Halozyme's stock price’s past reactions to earnings here.
According to InvestingPro, Halozyme's Financial Health score is "great performance".
Check out Halozyme's recent earnings performance, and Halozyme's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
HALO: is this perennial leader facing new challenges?
With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is HALO one of them?
Unlock ProPicks AI to find out